Peptide News Digest

Arrowhead $215M PRV Purchase, BioMarin Voxzogo Hits $1B Trajectory, Hims FTC Lawsuit + Monday Q2, PCAC Legal Analysis

Arrowhead pays $215M for PRV to accelerate plozasiran sHTG. Voxzogo Q2 $253M +14% on $1B trajectory. Hims Q2 Monday amid FTC lawsuit. PCAC rulemaking analysis.

4 stories · Covering regulatory, industry

Editor's Note

Saturday's follow-through news adds specificity to earlier-week earnings and pipeline stories. Arrowhead Pharmaceuticals (NASDAQ: ARWR) disclosed the terms of its Priority Review Voucher (PRV) acquisition first mentioned on the August 4 fiscal Q2 conference call: $215 million paid to an undisclosed seller under an asset purchase agreement expected to close in fiscal Q4 2026, applied to the plozasiran (Redemplo) supplemental new drug application (sNDA) for severe hypertriglyceridemia planned before year-end 2026 following the July 23 SHASTA-3 and SHASTA-4 positive Phase 3 results. Arrowhead projects a 3x return on the $215M PRV investment by shifting the plozasiran sHTG uptake curve forward by approximately four months. BioMarin's (NASDAQ: BMRN) Q2 2026 report Thursday delivered $253 million in Voxzogo (vosoritide) revenue (+14% YoY) despite the recent US launch of a competitive weekly dosing option, with approximately 90% of US pediatric patients on therapy retained through July; management now expects Voxzogo to reach $1 billion in annual sales, the first BioMarin franchise to cross that threshold. Hims & Hers Health (NYSE: HIMS) reports Q2 2026 earnings Monday August 10 after market close under the shadow of a Federal Trade Commission (FTC) lawsuit alleging the company shared consumer health information with third-party advertising platforms; Bank of America analyst Allen Lutz cut the HIMS price target to $30 from $37 while maintaining Hold. Wall Street expects Q2 revenue of $698.9 million (+28.3% YoY) with a -$0.05 EPS loss. And Holland & Knight and Mondaq legal analyses published following the July 23-24 PCAC vote clarified that HHS Secretary Robert F. Kennedy Jr. must formally approve the six peptides for 503A Bulks List inclusion, with no compounding permitted until final rulemaking completes (typically 12-24 months).

Regulatory

Arrowhead Pharmaceuticals (NASDAQ: ARWR) Discloses on Its August 4 Fiscal Q2 2026 Conference Call the Full Terms of the Priority Review Voucher (PRV) Acquisition: $215 Million Paid to an Undisclosed Seller Under an Asset Purchase Agreement Expected to Close in Fiscal Q4 2026, Applied to the Plozasiran (Redemplo, ApoC-III-Targeting siRNA) Supplemental New Drug Application (sNDA) for Severe Hypertriglyceridemia (sHTG) Planned Before End of 2026 Following the July 23, 2026 Phase 3 SHASTA-3 and SHASTA-4 Positive Readouts (79-81% Median Triglyceride Reduction, Significant Pancreatitis-Event Reduction); Arrowhead Projects a 3x Return on the $215 Million PRV Investment by Shifting the Plozasiran sHTG Uptake Curve Forward by Approximately Four Months (FDA Review Timeline Compressed From Standard 10 Months to 6 Months)

Arrowhead Pharmaceuticals (NASDAQ: ARWR) disclosed the full terms of its Priority Review Voucher (PRV) acquisition first mentioned on the August 4, 2026 fiscal Q2 2026 conference call. Terms: $215 million paid to an undisclosed seller under an asset purchase agreement expected to close in fiscal Q4 2026. Applied to: the plozasiran (Redemplo) supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG), planned for submission before end of 2026 following the July 23, 2026 Phase 3 SHASTA-3 and SHASTA-4 positive readouts (79% SHASTA-3 and 81% SHASTA-4 median triglyceride reductions at Month 12 versus approximately 27% for placebo, plus statistically significant reductions in acute pancreatitis events). Return projection: Arrowhead management projects a 3x return on the $215 million PRV investment by shifting the plozasiran sHTG commercial uptake curve forward by approximately four months (the PRV compresses FDA new drug application review from the standard 10-month timeline to a 6-month priority review timeline). PRVs are transferable FDA-issued regulatory instruments awarded to sponsors that develop drugs for rare pediatric diseases, tropical diseases, or specific medical countermeasures; recent secondary-market transactions have priced PRVs in the $100-250 million range depending on demand and pipeline urgency. Redemplo (plozasiran) was FDA-approved November 2025 for familial chylomicronemia syndrome; the sHTG indication would substantially expand the addressable patient population.

#arrowhead-pharmaceuticals #arwr #priority-review-voucher #prv #215-million #plozasiran #redemplo #severe-hypertriglyceridemia #sirna #apoc-iii #shasta-3 #shasta-4 #3x-return
Industry

BioMarin Pharmaceutical (NASDAQ: BMRN) Q2 2026 Earnings Detail: VOXZOGO (Vosoritide, C-Type Natriuretic Peptide Analog for Achondroplasia in Pediatric Patients) Delivered $253 Million in Revenue (+14% Year-Over-Year) Despite the Recent US Launch of a Competitive Weekly Dosing Option, With Approximately 90% of US Pediatric Patients on Therapy Retained Through July; Management Now Expects VOXZOGO to Reach at Least $1 Billion in Annual Sales, Making It BioMarin's First Product to Achieve the Blockbuster Threshold; Amicus Therapeutics Acquisition Integration Adding GALAFOLD (Migalastat for Fabry) and POMBILITI + OPFOLDA (Cipaglucosidase Alfa Plus Miglustat for Late-Onset Pompe Disease) Expected to Deliver $220 Million in Non-GAAP Cost Synergies Fully Realized by 2028

BioMarin Pharmaceutical (NASDAQ: BMRN) Q2 2026 earnings detail: VOXZOGO (vosoritide, C-type natriuretic peptide analog administered as a daily subcutaneous injection for achondroplasia in pediatric patients) delivered $253 million in revenue (+14% year-over-year) despite the recent US launch of a competitive weekly dosing option (BridgeBio's infigratinib for children with achondroplasia). Approximately 90% of US pediatric patients on VOXZOGO therapy remained on treatment through July, addressing prior investor concerns about competitive pressure. Management now expects VOXZOGO to reach at least $1 billion in annual sales, making it BioMarin's first product to achieve the blockbuster threshold. Broader Q2 2026 revenue of $990 million (+20% YoY) beat consensus by a wide margin; non-GAAP diluted EPS of $0.54 beat $0.23 consensus. The Amicus Therapeutics acquisition integration adds GALAFOLD (migalastat for Fabry disease) and POMBILITI + OPFOLDA (cipaglucosidase alfa plus miglustat oral chaperone for late-onset Pompe disease) to the BioMarin rare-disease portfolio, with $220 million in non-GAAP cost synergies expected to be fully realized by 2028. The Amicus deal also positions BioMarin to accelerate non-GAAP diluted EPS accretion beginning 2027 with the integrated commercial and manufacturing infrastructure absorbing GALAFOLD and Pompe franchises. BioMarin raised full-year 2026 guidance on both revenue and non-GAAP diluted EPS.

#biomarin #bmrn #voxzogo #vosoritide #1-billion-blockbuster #achondroplasia #infigratinib #bridgebio #amicus-therapeutics #galafold #pombiliti #opfolda #fabry-disease #pompe-disease #cost-synergies
Industry

Hims & Hers Health (NYSE: HIMS) Q2 2026 Earnings Preview for Monday August 10 After Market Close Under the Shadow of a Federal Trade Commission (FTC) Lawsuit Alleging the Company Shared Consumer Sensitive Health Information With Third-Party Advertising Platforms; Wall Street Consensus at $698.9 Million Revenue (+28.3% Year-Over-Year) and Approximately -$0.05 Diluted EPS Loss Compared to +$0.17 EPS in Q2 2025; Bank of America Analyst Allen Lutz Cut the HIMS Price Target to $30 From $37 (While Maintaining Hold) Citing FTC-Lawsuit Uncertainty With Small-Fee Base-Case Framing; Options Traders Are Pricing an Approximate 14.5% Post-Earnings Move in Either Direction

Hims & Hers Health (NYSE: HIMS) reports Q2 2026 earnings Monday August 10, 2026 after market close under the shadow of a Federal Trade Commission (FTC) lawsuit alleging the company shared consumer sensitive health information with third-party advertising platforms without meeting HIPAA-compatible informed-consent requirements. Wall Street consensus: $698.9 million revenue (+28.3% year-over-year) and approximately -$0.05 diluted EPS loss versus +$0.17 EPS in the year-ago quarter. Bank of America analyst Allen Lutz cut the HIMS price target to $30 from $37 (maintaining Hold), citing FTC-lawsuit uncertainty with a small-fee base-case framing. Options traders are pricing an approximate 14.5% post-earnings move in either direction. Analyst focus areas beyond top-line numbers: post-PCAC peptide-compounding revenue trajectory (Leerink estimates $440 million peptide sales in 2026 representing 15% of the projected revenue midpoint); FTC lawsuit financial and operational impact; branded GLP-1 (Wegovy/Ozempic/Zepbound/Mounjaro) commercial partnership contribution since Q1 2026; and Chief Medical Officer Dr. Anant Vinjamoori's July 23 PCAC harm-reduction testimony framing for the Hims peptide strategy narrative. Truist analysts have cautioned that substantial peptide revenue is unlikely before 2028 even with the PCAC advisory support given the 12-24 month FDA rulemaking timeline.

#hims-hers #hims #q2-2026-earnings-preview #ftc-lawsuit #consumer-health-information #third-party-advertising #bofa #allen-lutz #price-target-cut #leerink #peptide-revenue
Regulatory

Holland & Knight and Mondaq Legal Analyses Published Following the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) Vote Clarify the Rulemaking Process for the Six Recommended Peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon): HHS Secretary Robert F. Kennedy Jr. Must Formally Approve the Substances for 503A Bulks List Inclusion, and No Compounding Is Permitted Until Final Rulemaking Completes (Typically 12-24 Months From Advisory-Committee Recommendation); The FDA Has Announced a Second PCAC Peptide Meeting Before the End of February 2027 to Review Five Additional Peptides (Cathelicidin/LL-37, GHK-Cu, Dihexa Acetate, Melanotan II, PEG-MGF)

Holland & Knight and Mondaq legal analyses published following the July 23-24, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) vote clarify the rulemaking process for the six recommended peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon; Emideltide/DSIP rejected). Key legal clarifications: PCAC recommendations are advisory only; HHS Secretary Robert F. Kennedy Jr. must formally approve the substances for Section 503A Bulks List inclusion; no compounding pharmacy is permitted to legally compound the peptides until final rulemaking completes; formal rulemaking typically takes 12-24 months from advisory-committee recommendation (Notice of Proposed Rulemaking, public comment period, response to comments, final rule with effective date). Even after final rule takes effect, individual states retain authority under state pharmacy board oversight to further restrict or condition compounded-peptide preparation. Separately, the FDA has announced a second PCAC peptide meeting before the end of February 2027 to review five additional peptides: cathelicidin (LL-37, antimicrobial peptide), GHK-Cu (copper tripeptide cosmetic peptide), dihexa acetate (nootropic), melanotan II (α-MSH analog), and pegylated mechano growth factor (PEG-MGF, muscle repair). Combined, the July 2026 and February 2027 PCAC dockets bring 12 peptides through advisory-committee review as part of the broader Trump administration and HHS Secretary RFK Jr. peptide deregulation agenda that has moved through the regulatory system since Q1 2026.

#pcac #fda #holland-knight #mondaq #legal-analysis #503a-bulks-list #hhs-secretary #rfk-jr #rulemaking-timeline #state-pharmacy-boards #february-2027-meeting #cathelicidin #ghk-cu